Jiaxing Antidote Biopharmaceutical

Antidote Biopharmaceutical is a clinical-stage biotechnology company based in Jiaxing, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on high-value biologics, particularly monoclonal antibodies targeting the interleukin pathway to treat conditions such as psoriasis and atopic dermatitis. Their lead candidate, AD-011, is a recombinant humanized anti-IL-17A monoclonal antibody currently undergoing clinical evaluation. Antidote Biopharmaceutical aims to provide more accessible and effective treatment options for patients with chronic inflammatory disorders through its robust R&D and manufacturing capabilities.